AR and prostate carcinoma: Androgen synthesis inhibitors (GnRH agonists/antagonists, abiraterone acetate) and AR inhibitors (enzalutamide, bicalutamide) play a major role in treating prostate cancer, another androgen driven disease, and possibly may benefit patients with PSCC.